Skip to content
The Microdose (UC Berkeley BCSP)· Robin Berghaus·· 7 days agoAI score62

FDA said to end priority voucher program as Compass Pathways files psilocybin application

FDA said to end speedy drug review program while Compass Pathways submits FDA New Drug Application for psilocybin; Feds commit $25 million for ibogaine and “psychotropic” research

AI summary

Reuters reported that the US FDAThe Food and Drug Administration, the United States regulator of medicines, medical devices and food.Open the glossary is ending the Commissioner's National Priority Voucher program, which had compressed a 10-12 month drug review to 1-2 months. Three psychedelics-related voucher holders are affected, including Compass Pathways' COMP360 for treatment-resistant depressionDepression that has not improved enough after adequate courses of at least two antidepressant treatments.Open the glossary, Usona Institute's psilocybin for major depressive disorder and Transcend Therapeutics' methylone for PTSDPost-traumatic stress disorder, a mental health condition that can follow exposure to a traumatic event.Open the glossary.

Key facts

Jurisdiction
United States
Source
The Microdose (UC Berkeley BCSP) (themicrodose.substack.com)
Published
How this summary was made

The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: The Microdose (UC Berkeley BCSP) · themicrodose.substack.com

Connected to

Jurisdiction
United States

Other recent items on these topics